Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

Hematol Oncol. 2018 Feb;36(1):360-362. doi: 10.1002/hon.2466. Epub 2017 Jul 21.

Affiliations

¹ Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
² Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
³ Tumor Immunology Unit, Department of Health Science, Human Pathology Section, University of Palermo, School of Medicine, Palermo, Italy.

PMID: 28730742
DOI: 10.1002/hon.2466

No abstract available

Publication types

Letter

MeSH terms

Animals
Enzyme Inhibitors / pharmacology*
Glucuronidase / antagonists & inhibitors*
Glucuronidase / metabolism
Humans
Lymphoma / drug therapy*
Lymphoma / enzymology
Mice
Neoplasm Proteins / antagonists & inhibitors*
Neoplasm Proteins / metabolism
Tumor Microenvironment / drug effects*
Xenograft Model Antitumor Assays

Substances

Enzyme Inhibitors
Neoplasm Proteins
heparanase
Glucuronidase